This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
polycythemia-vera
Polycythemia Vera
Polycythemia vera is a JAK2-driven MPN with erythrocytosis, thrombocytosis, and leukocytosis; JAK2 V617F ~99%; phlebotomy + low-dose aspirin for all; hydroxyurea or ropeginterferon alfa-2b for high-risk; ruxolitinib for HU-resistant; MF/AML transformation risk.
Entry Metadata
| Field | Value |
|---|---|
| ID | polycythemia-vera |
| Name | Polycythemia Vera |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-435. · PubMed 25577388
- Gisslinger H, Gotic M, Holowiecki J, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196-e208. · PubMed 32046833